Acute pancreatitis, acute exacerbation stage of chronic recurrent pancreatitis,postoperative acute pancreatitis, disseminated intravascular coagulation (DIC) 急性胰臟炎、伴有蛋白分解酵素逸脫之胰臟疾患症狀之緩解、泛發性血管內血液凝固症

1.化學合成的蛋白分解酵素阻斷劑。
2.可抑制血液凝固因子的消耗。並可預防腎或肺內血栓之形成。

人新鮮血添加C-Gabexate mesilate時，其半衰期約60秒。健康志願者靜脈給藥Gabexate mesilate 10mg/kg時，血中濃度成級數遞減，半衰期約為55秒。健康男性志願者，持續靜脈注射Gabexate mesilate 2mg/kg/hr，其血中濃度在給藥5-10分鐘達到穩定狀態，其未變化體Gabexate mesilate血中濃度為109 ng/kg。

cerebral aneurysm or cerebrovascular hemorrhage, severe anduncontrolled hypertension, Uncontrolled bleeding (except for disseminated intravascular coagulation or hemodialysis patients with active bleeding sites/hemostatic function impairment)

孕婦或有懷孕可能之婦人應避免大量給藥。(動物實驗老鼠大量給藥100mg/kg/day有胎仔體重減少之情形發生)

Phlebitis, vascular pain, reddening and inflammatory at injection site, BP, acceleration of bleeding tendency, nausea

IVF
1.Pancreatitis：
Adults: 100-300mg/day at a rate 8ml/min and the dosage depending on the improvement of the symptoms
2.Disseminated intravascular coagulation：20-39mg/kg over 24 hrs

藥品應置於攝氏 15 ~ 25 度乾燥處所；如發生變質或過期，不可再使用。